This single-family office represents private family interests in the United States. The firm is flexible in terms of investment size but generally looks to invest at least several hundred thousand dollars per round, depending on round size and anticipated capital requirements. The firm prefers Series A and later-stage companies, while pre-Series A opportunities are considered depending on technology maturity. Currently, the firm invests primarily in companies based in North America.
The firm seeks breakthrough technologies with a strong social impact focus in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to existing medical procedures and treatments. Areas of particular interest include optical and sound-based technologies, devices that reduce reliance on drug-based treatments, orthopedics, gene and nucleic acid-based therapies, immuno-oncology, and technologies addressing sensory loss.
The firm reviews co-investment opportunities in private companies and, on an opportunistic basis, may consider investments in micro- and small-cap public companies as a direct investor. The firm seeks companies that have completed seed financing and have reached key intellectual property milestones, including allowance of claims by relevant patent authorities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 